THE EFFECT OF COMBINATION THERAPY WITH PEGINTERFERON ALFA-2B PLUS ENTECAVIR DURING 48 WEEKS FOR CHRONIC HEPATITIS B

被引：0
|
作者：
Inuzuka, Tadashi [1 ]
Takeda, Haruhiko [1 ]
Kanesaka, Takashi [1 ]
Kanesaka, Takashi [1 ]
Nakajima, Jun [1 ]
Matsuda, Fumihiro [1 ]
Sakamoto, Azusa [1 ]
Hatamaru, Keiichi [1 ]
Henmi, Shinichiro [1 ]
Ishikawa, Tetsuro [1 ]
Saito, Sumio [1 ]
Saito, Sumio [1 ]
Nishikawa, Hiroki [1 ]
Nishikawa, Hiroki [1 ]
Kita, Ryuichi [1 ]
Kimura, Toru [1 ]
Osaki, Yukio [1 ]
机构：
[1] Osaka Red Cross Hosp, Osaka, Japan
来源：
HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：1063A / 1063A
页数：1
相关论文
共 50 条
  • [31] The cost-effectiveness analysis of combination of peginterferon alfa-2a and ribavirin versus combination of peginterferon alfa-2b and ribavirin in chronic hepatitis C in Poland
    Orlewska, E
    VALUE IN HEALTH, 2004, 7 (03) : 356 - 356
  • [32] Peginterferon alfa-2b as monotherapy or in combination with lamivudine in patients with HeAg-negative chronic hepatitis B: A randomised study
    Papadopoulos, Vasilelos P.
    Chrysagis, Dimitrios N.
    Protopapas, Andreas N.
    Goulis, Ioannis G.
    Dimitriadis, Georgios T.
    Mimidis, Konstantinos P.
    MEDICAL SCIENCE MONITOR, 2009, 15 (02): : CR56 - CR61
  • [33] Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C
    Davis, GL
    Wong, JB
    McHutchison, JG
    Manns, MP
    Harvey, J
    Albrecht, J
    HEPATOLOGY, 2003, 38 (03) : 645 - 652
  • [34] Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B
    Marcellin, P.
    Ahn, S. H.
    Chuang, W. -L.
    Hui, A. J.
    Tabak, F.
    Mehta, R.
    Petersen, J.
    Lee, C. -M.
    Ma, X.
    Caruntu, F. A.
    Tak, W. Y.
    Elkhashab, M.
    Lin, L.
    Wu, G.
    Martins, E. B.
    Charuworn, P.
    Yee, L. J.
    Lim, S. G.
    Foster, G. R.
    Fung, S.
    Morano, L.
    Samuel, D.
    Agarwal, K.
    Idilman, R.
    Strasser, S. I.
    Buti, M.
    Gaeta, G. B.
    Papatheodoridis, G.
    Flisiak, R.
    Chan, H. L. Y.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2016, 44 (09) : 957 - 966
  • [35] Hepatitis c virus dynamics during therapy with peginterferon ALFA-2A (PEGASYS®) compared to peginterferon ALFA-2B (PEGINTRON®) in naive patients with chronic Hepatitis C.
    Bruno, R
    Debiaggi, M
    Ciappina, V
    Maffezzini, E
    Patruno, S
    Sacchi, P
    Filice, G
    HEPATOLOGY, 2002, 36 (04) : 206A - 206A
  • [36] Costs of antiviral treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.
    Siebert, U
    Sroczynski, G
    Wasem, J
    Aidelsburger, P
    Rossol, S
    Wong, JB
    HEPATOLOGY, 2002, 36 (04) : 598A - 598A
  • [37] Generalized nummular eczema secondary to peginterferon Alfa-2b and ribavirin combination therapy for hepatitis C infection
    Shen, Y
    Pielop, J
    Hsu, S
    ARCHIVES OF DERMATOLOGY, 2005, 141 (01) : 102 - 103
  • [38] Clinical and persistency outcomes in hepatitis C patients treated with peginterferon alfa-2a or peginterferon alfa-2b plus ribavirin
    Hassanein, T. I.
    Ye, X.
    Blumentals, W. A.
    Brixner, D. I.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S295 - S296
  • [39] Population pharmacokinetics of peginterferon alfa-2b in pediatric patients with chronic hepatitis C
    Xu, C.
    Gupta, S.
    Krishna, G.
    Cutler, D.
    Wirth, S.
    Galoppo, C.
    Ciocca, M.
    Kolz, K.
    Noviello, S.
    Sniukiene, V.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (12) : 2045 - 2054
  • [40] Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C
    Krawitt, EL
    Ashikaga, T
    Gordon, SR
    Ferrentino, N
    Ray, MA
    Lidofsky, SD
    JOURNAL OF HEPATOLOGY, 2005, 43 (02) : 243 - 249
12345